Successful Use of the New Immune-suppressor Sirolimus in IPEX (Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked Syndrome)
Open Access
- 31 August 2005
- journal article
- case report
- Published by Elsevier BV in The Journal of Pediatrics
- Vol. 147 (2), 256-259
- https://doi.org/10.1016/j.jpeds.2005.04.017
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Autoimmune enteropathy: molecular conceptsCurrent Opinion in Gastroenterology, 2004
- Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25– T cellsJCI Insight, 2003
- An essential role for Scurfin in CD4+CD25+ T regulatory cellsNature Immunology, 2003
- Foxp3 programs the development and function of CD4+CD25+ regulatory T cellsNature Immunology, 2003
- Control of Regulatory T Cell Development by the Transcription Factor Foxp3Science, 2003
- Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndromeJournal of Medical Genetics, 2002
- Scurfin (FOXP3) Acts as a Repressor of Transcription and Regulates T Cell ActivationPublished by Elsevier BV ,2001
- Treatment of the Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked Syndrome (IPEX) by Allogeneic Bone Marrow TransplantationThe New England Journal of Medicine, 2001
- Immunopurified Mammalian Target of Rapamycin Phosphorylates and Activates p70 S6 Kinase α in VitroPublished by Elsevier BV ,1999
- Treatment of pediatric autoimmune enteropathy with tacrolimus (FK506)Gastroenterology, 1996